Rapport Therapeutics Quote - RAPP

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

19.48

Bid

18.26

Ask

20.14

Volume

107,939

18.15 Day's Range 19.61

16.55 52 Week Range 29.74

Market Cap

712.509M

Previous Close

18.39

Open

18.58

Last Trade

150

19.48

(priorref)

Last Trade Time

Financial Volume

US$ 2,018,990

VWAP

18.7049

Average Volume (3m)

108,720

Shares Outstanding

36,576,457

Dividend Yield

PE Ratio

-20.40

Earnings Per Share (EPS)

-0.95

Revenue

Net Profit

-34.79M

Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational sma... Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Headquarters

New Castle, Delaware, USA

Founded

Rapport Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RAPP. The last closing price for Rapport Therapeutics was US$18.39. Over the last year, Rapport Therapeutics shares have traded in a share price range of US$ 16.55 to US$ 29.74.

Rapport Therapeutics currently has 36,576,457 shares outstanding. The market capitalization of Rapport Therapeutics is US$672.64 million. Rapport Therapeutics has a price to earnings ratio (PE ratio) of -20.40.

Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures

A 30% reduction in long episodes was shown to be associated with a 50% or greater reduction in clinical seizures in a post-hoc analysis, validating the biomarker for proof-of-concept studies...

Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting

BOSTON and SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update

Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and operational leadershipRAP-219 MAD-2 and PET trials...

Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November

BOSTON and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of small molecule...

Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences

BOSTON and SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of...

Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit

BOSTON and SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.42	2.20356768101	19.06	20.22	17.01	79077	18.30136683	CS
4	-0.43	-2.1597187343	19.91	21.86	17.01	134612	18.98102024	CS
12	-0.83	-4.0866568193	20.31	29.74	17.01	108720	22.11329979	CS
26	-6.01	-23.577873676	25.49	29.74	16.55	133965	21.49715388	CS
52	1.48	8.22222222222	18	29.74	16.55	154109	21.88125778	CS
156	1.48	8.22222222222	18	29.74	16.55	154109	21.88125778	CS
260	1.48	8.22222222222	18	29.74	16.55	154109	21.88125778	CS

RAPP - Frequently Asked Questions (FAQ)

What is the current Rapport Therapeutics share price?

The current share price of Rapport Therapeutics is US$ 19.48

How many Rapport Therapeutics shares are in issue?

Rapport Therapeutics has 36,576,457 shares in issue

What is the market cap of Rapport Therapeutics?

The market capitalisation of Rapport Therapeutics is USD 672.64M

What is the 1 year trading range for Rapport Therapeutics share price?

Rapport Therapeutics has traded in the range of US$ 16.55 to US$ 29.74 during the past year

What is the PE ratio of Rapport Therapeutics?

The price to earnings ratio of Rapport Therapeutics is -20.4

What is the reporting currency for Rapport Therapeutics?

Rapport Therapeutics reports financial results in USD

What is the latest annual profit for Rapport Therapeutics?

The latest annual profit of Rapport Therapeutics is USD -34.79M

What is the registered address of Rapport Therapeutics?

The registered address for Rapport Therapeutics is 1209 ORANGE STREET, IN THE CITY OF WILMINGTON, NEW CASTLE, DELAWARE, 19801

Which industry sector does Rapport Therapeutics operate in?

Rapport Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
FCUVFocus Universal Inc	US$ 0.9499 (174.93%)	260.93M
NITON2OFF Inc	US$ 2.6306 (145.85%)	358.28M
CRNCCerence Inc	US$ 19.33 (143.76%)	161.8M
KITTNauticus Robotics Inc	US$ 3.8249 (140.56%)	104.8M
ACONAclarion Inc	US$ 0.2984 (110.14%)	305.64M
HWHHWH International Inc	US$ 0.4621 (-28.80%)	7.43M
SMSTDefiance Daily Target 2x Short MSTR ETF	US$ 5.69 (-26.30%)	24.77M
RAINRain Enhancement Technologies Holdco Inc	US$ 5.59 (-23.42%)	161.15k
PTLEPTL Ltd	US$ 9.35 (-23.30%)	1.04M
NXUNXU Inc	US$ 0.725868 (-22.78%)	7.59M
NITON2OFF Inc	US$ 2.6306 (145.85%)	358.28M
TGLTreasure Global Inc	US$ 0.382 (101.58%)	337.5M
ACONAclarion Inc	US$ 0.2984 (110.14%)	305.64M
FCUVFocus Universal Inc	US$ 0.9499 (174.93%)	260.93M
NVDANVIDIA Corporation	US$ 144.47 (4.45%)	230.01M